255 related articles for article (PubMed ID: 32494134)
21. Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest.
Xie Y; Zeng X; Wu X; Hu J; Zhu Y; Yang X
Nanomedicine (Lond); 2018 Apr; 13(8):887-898. PubMed ID: 29473458
[TBL] [Abstract][Full Text] [Related]
22. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Mao J; Meng X; Zhao C; Yang Y; Liu G
Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310
[TBL] [Abstract][Full Text] [Related]
23. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
24. Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion.
Li J; Liu J; Li S; Hao Y; Chen L; Zhang X
Oncotarget; 2016 Mar; 7(12):13782-96. PubMed ID: 26883109
[TBL] [Abstract][Full Text] [Related]
25. FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy.
He C; Lu S; Wang XZ; Wang CC; Wang L; Liang SP; Luo TF; Wang ZC; Piao MH; Chi GF; Ge PF
Acta Pharmacol Sin; 2021 Aug; 42(8):1324-1337. PubMed ID: 33879840
[TBL] [Abstract][Full Text] [Related]
26. Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.
Meng X; Zhao Y; Han B; Zha C; Zhang Y; Li Z; Wu P; Qi T; Jiang C; Liu Y; Cai J
Nat Commun; 2020 Jan; 11(1):594. PubMed ID: 32001707
[TBL] [Abstract][Full Text] [Related]
27. SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment.
Liu H; Li Y; Mozhi A; Zhang L; Liu Y; Xu X; Xing J; Liang X; Ma G; Yang J; Zhang X
Biomaterials; 2014 Aug; 35(24):6519-33. PubMed ID: 24797882
[TBL] [Abstract][Full Text] [Related]
28. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
[TBL] [Abstract][Full Text] [Related]
29. Sialic Acid-Targeted Nanovectors with Phenylboronic Acid-Grafted Polyethylenimine Robustly Enhance siRNA-Based Cancer Therapy.
Ji M; Li P; Sheng N; Liu L; Pan H; Wang C; Cai L; Ma Y
ACS Appl Mater Interfaces; 2016 Apr; 8(15):9565-76. PubMed ID: 27007621
[TBL] [Abstract][Full Text] [Related]
30. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
31. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
32. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
33. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
34. Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.
Filippi-Chiela EC; Thomé MP; Bueno e Silva MM; Pelegrini AL; Ledur PF; Garicochea B; Zamin LL; Lenz G
BMC Cancer; 2013 Mar; 13():147. PubMed ID: 23522185
[TBL] [Abstract][Full Text] [Related]
35. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
36. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Ding Y; Zhou Y; Li Z; Zhang H; Yang Y; Qin H; Xu Q; Zhao L
Life Sci; 2020 Nov; 260():118411. PubMed ID: 32918978
[TBL] [Abstract][Full Text] [Related]
37. All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Ran D; Zhou J; Chai Z; Li J; Xie C; Mao J; Lu L; Zhang Y; Wu S; Zhan C; Lu W
Theranostics; 2020; 10(9):4073-4087. PubMed ID: 32226540
[TBL] [Abstract][Full Text] [Related]
38. Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Shao N; Mao J; Xue L; Wang R; Zhi F; Lan Q
J Neurooncol; 2019 Jan; 141(2):277-288. PubMed ID: 30460630
[TBL] [Abstract][Full Text] [Related]
39. Comparison of cationic liposome and PAMAM dendrimer for delivery of anti-Plk1 siRNA in breast cancer treatment.
Bulbake U; Kommineni N; Ionov M; Bryszewska M; Khan W
Pharm Dev Technol; 2020 Jan; 25(1):9-19. PubMed ID: 30633621
[TBL] [Abstract][Full Text] [Related]
40. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
